PATENT CLAIM ANALYSIS

Application Number: 16274579
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["435", "006110"]

Abstract:
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

Claim (Index 13):
The method of  claim 11 , wherein said chemotherapy agent is at least one of cisplatin and ifosfamide.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 99.0
- Lexical Diversity: 1.36538
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13729175', '14707087', '14707363', '14707391', '10629318']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5475447558795716
- 35 USC 102 Novelty (BERT): 0.4711195729578616
- Combined Prediction Score: 0.5399022375874006
- Mean Citation Score: 159.24409400000005
- Max Citation Score: 173.04588
- Similarity Product: 139.916101906271

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test